FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $224,000 | -33.7% | 5,780 | 0.0% | 0.16% | -31.2% |
| Q4 2021 | $338,000 | -8.4% | 5,780 | -7.2% | 0.24% | -10.2% |
| Q3 2021 | $369,000 | -36.5% | 6,230 | -7.0% | 0.26% | -29.4% |
| Q2 2021 | $581,000 | +5.3% | 6,700 | 0.0% | 0.37% | 0.0% |
| Q1 2021 | $552,000 | -22.7% | 6,700 | -14.6% | 0.37% | -24.6% |
| Q4 2020 | $714,000 | +132.6% | 7,850 | +2.3% | 0.50% | +95.3% |
| Q3 2020 | $307,000 | +16.7% | 7,670 | 0.0% | 0.25% | +2.0% |
| Q2 2020 | $263,000 | -44.5% | 7,670 | -68.3% | 0.25% | -33.8% |
| Q1 2020 | $474,000 | 0.0% | 24,200 | 0.0% | 0.38% | 0.0% |
| Q4 2019 | $474,000 | +25.7% | 24,200 | -0.2% | 0.38% | +15.0% |
| Q3 2019 | $377,000 | -32.6% | 24,250 | -12.0% | 0.33% | -30.1% |
| Q2 2019 | $559,000 | +16.0% | 27,550 | +0.4% | 0.47% | +14.1% |
| Q1 2019 | $482,000 | +3.7% | 27,450 | -24.3% | 0.41% | +20.6% |
| Q4 2018 | $465,000 | -10.6% | 36,260 | +13.5% | 0.34% | +25.0% |
| Q3 2018 | $520,000 | +54.8% | 31,935 | +7.8% | 0.27% | +49.5% |
| Q2 2018 | $336,000 | +16.7% | 29,635 | +0.5% | 0.18% | +20.5% |
| Q1 2018 | $288,000 | +234.9% | 29,490 | +110.6% | 0.15% | +277.5% |
| Q4 2017 | $86,000 | – | 14,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |